This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.

This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.

The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such and manufacture of such using a relatively small convenient and orally comfortable dosage form (e.g. tablet) size.

The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The dosage forms include ODTs and non- ODTs effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.

The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The tablets include ODTs and non- ODTs effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.